LFLorenza Fusi
Lorenza Fusi
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lorenza Fusi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- David Schrama
Department of Dermatology, University Hospital Würzburg, Würzburg, Germany
2 shared publications - Marc Schmidt
Department of Dermatology, Venereology and Allergology University Hospital Würzburg Würzburg Germany
2 shared publications - Matthias Goebeler
Klinik für Dermatologie Venerologie und Allergologie Universitätsklinikum Würzburg Würzburg Deutschland
2 shared publications Andreas Schlosser
Rudolf Virchow Center, Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany
1 shared publication- Christian Adam
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
1 shared publication - Hermann Kneitz
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany
1 shared publication
Latest Publications
- Open Access
- 11 February 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (3) , 101714
Interaction of transcription factor FoxO3 with histone acetyltransferase complex subunit TRRAP modulates gene expression and apoptosis
- 11 February 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (3) , 101714
Open AccessInteraction of transcription factor FoxO3 with histone acetyltransferase complex subunit TRRAP modulates gene expression and apoptosis
- 1 December 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (12) , 2455-2465.e10
Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways
- 1 December 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (12) , 2455-2465.e10
Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways